LINC00616

Across TCGA pan-cancer cohorts, LINC00616 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of LINC00616’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where LINC00616 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC00616 is over-expressed in tumor.

PAAD and UCEC are the cancer types where LINC00616 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC00616 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PAAD	All	All	+0.212	.023	2	view →
UCEC	All	All	+0.035	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

LINC00616–PAAD

Open the PAAD breakdown →